Insider Buying: Cocrystal Pharma (NASDAQ:COCP) Director Purchases 50,000 Shares of Stock

Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Phillip Md Et Al Frost bought 50,000 shares of Cocrystal Pharma stock in a transaction on Wednesday, December 31st. The shares were acquired at an average price of $0.95 per share, for a total transaction of $47,500.00. Following the completion of the acquisition, the director owned 1,838,551 shares in the company, valued at $1,746,623.45. This represents a 2.80% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Tuesday, December 30th, Phillip Md Et Al Frost purchased 20,000 shares of Cocrystal Pharma stock. The stock was acquired at an average price of $0.97 per share, with a total value of $19,400.00.
• On Friday, December 26th, Phillip Md Et Al Frost acquired 40,000 shares of Cocrystal Pharma stock. The shares were bought at an average cost of $0.97 per share, for a total transaction of $38,800.00.
• On Wednesday, December 24th, Phillip Md Et Al Frost acquired 25,000 shares of Cocrystal Pharma stock. The stock was bought at an average price of $0.97 per share, for a total transaction of $24,250.00.
• On Wednesday, November 26th, Phillip Md Et Al Frost bought 4,000 shares of Cocrystal Pharma stock. The stock was bought at an average price of $0.99 per share, with a total value of $3,960.00.
• On Tuesday, November 25th, Phillip Md Et Al Frost bought 20,000 shares of Cocrystal Pharma stock. The shares were bought at an average cost of $0.94 per share, with a total value of $18,800.00.

Cocrystal Pharma Stock Up 1.4%

NASDAQ COCP traded up $0.01 during trading hours on Friday, hitting $0.99. 34,253 shares of the company were exchanged, compared to its average volume of 68,864. The firm has a market cap of $13.68 million, a price-to-earnings ratio of -1.06 and a beta of 1.13. The company has a 50 day moving average of $1.03 and a two-hundred day moving average of $1.31. Cocrystal Pharma, Inc. has a 52-week low of $0.90 and a 52-week high of $2.67.

Cocrystal Pharma (NASDAQ:COCP) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.03. On average, equities research analysts predict that Cocrystal Pharma, Inc. will post -1.85 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cocrystal Pharma in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.